Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The risk of radiation-induced neurocognitive impairment and the impact of sparing the hippocampus during pediatric proton cranial irradiation

The risk of radiation-induced neurocognitive impairment and the impact of sparing the hippocampus... Abstract Background and purpose Hippocampus is a central component for neurocognitive function and memory. We investigated the predicted risk of neurocognitive impairment of craniospinal irradiation (CSI) and the deliverability and effects of hippocampal sparing. The risk estimates were derived from published NTCP models. Specifically, we leveraged the estimated benefit of reduced neurocognitive impairment with the risk of reduced tumor control. Material and methods For this dose planning study, a total of 504 hippocampal sparing intensity modulated proton therapy (HS-IMPT) plans were generated for 24 pediatric patients whom had previously received CSI. Plans were evaluated with respect to target coverage and homogeneity index to target volumes, maximum and mean dose to OARs. Paired t-tests were used to compare hippocampal mean doses and normal tissue complication probability estimates. Results The median mean dose to the hippocampus could be reduced from 31.3 GyRBE to 7.3 GyRBE (p < .001), though 20% of these plans were not considered clinically acceptable as they failed one or more acceptance criterion. Reducing the median mean hippocampus dose to 10.6 GyRBE was possible with all plans considered as clinically acceptable treatment plans. By sparing the hippocampus to the lowest dose level, the risk estimation of neurocognitive impairment could be reduced from 89.6%, 62.1% and 51.1% to 41.0% (p < .001), 20.1% (p < .001) and 29.9% (p < .001) for task efficiency, organization and memory, respectively. Estimated tumor control probability was not adversely affected by HS-IMPT, ranging from 78.5 to 80.5% for all plans. Conclusions We present estimates of potential clinical benefit in terms of neurocognitive impairment and demonstrate the possibility of considerably reducing neurocognitive adverse effects, minimally compromising target coverage locally using HS-IMPT. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Oncologica Taylor & Francis

The risk of radiation-induced neurocognitive impairment and the impact of sparing the hippocampus during pediatric proton cranial irradiation

Download PDF
7 pages

Loading next page...
 
/lp/taylor-francis/the-risk-of-radiation-induced-neurocognitive-impairment-and-the-impact-AftT2GEoh0

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Taylor & Francis
Copyright
© 2023 Acta Oncologica Foundation
ISSN
1651-226X
eISSN
0284-186X
DOI
10.1080/0284186X.2023.2176253
Publisher site
See Article on Publisher Site

Abstract

Abstract Background and purpose Hippocampus is a central component for neurocognitive function and memory. We investigated the predicted risk of neurocognitive impairment of craniospinal irradiation (CSI) and the deliverability and effects of hippocampal sparing. The risk estimates were derived from published NTCP models. Specifically, we leveraged the estimated benefit of reduced neurocognitive impairment with the risk of reduced tumor control. Material and methods For this dose planning study, a total of 504 hippocampal sparing intensity modulated proton therapy (HS-IMPT) plans were generated for 24 pediatric patients whom had previously received CSI. Plans were evaluated with respect to target coverage and homogeneity index to target volumes, maximum and mean dose to OARs. Paired t-tests were used to compare hippocampal mean doses and normal tissue complication probability estimates. Results The median mean dose to the hippocampus could be reduced from 31.3 GyRBE to 7.3 GyRBE (p < .001), though 20% of these plans were not considered clinically acceptable as they failed one or more acceptance criterion. Reducing the median mean hippocampus dose to 10.6 GyRBE was possible with all plans considered as clinically acceptable treatment plans. By sparing the hippocampus to the lowest dose level, the risk estimation of neurocognitive impairment could be reduced from 89.6%, 62.1% and 51.1% to 41.0% (p < .001), 20.1% (p < .001) and 29.9% (p < .001) for task efficiency, organization and memory, respectively. Estimated tumor control probability was not adversely affected by HS-IMPT, ranging from 78.5 to 80.5% for all plans. Conclusions We present estimates of potential clinical benefit in terms of neurocognitive impairment and demonstrate the possibility of considerably reducing neurocognitive adverse effects, minimally compromising target coverage locally using HS-IMPT.

Journal

Acta Oncologica – Taylor & Francis

Published: Feb 1, 2023

Keywords: Neurocognitive impairment; normal tissue complication probability; tumor control probability; craniospinal irradiation; hippocampal avoidance; pediatric hippocampus

References

  • Classification, incidence and survival analyses of children with CNS tumours diagnosed in Sweden 1984-2005
  • Factors affecting the prognosis of children with medulloblastoma: a single institution retrospective analysis of 40 cases
  • Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma
  • Assessment of the long-term effects of primary radiation therapy for brain tumors in children
  • Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma
  • Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique
  • Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial
  • Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study
  • Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study
  • Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy
  • Caring for survivors of childhood cancers: the size of the problem
  • Change in neurocognitive functioning after treatment with cranial radiation in childhood
  • Late effects after radiotherapy for childhood low-grade glioma
  • Long-term intellectual outcome in childre with posterior fossa tumors according to radiation doses and volumes
  • Unmet rehabilitation needs in 86% of Norwegian paediatric embryonal brain tumor survivors
  • Regional susceptibility to dose-dependent white matter damage after brain radiotherapy
  • Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline
  • Neurogenesis in the adult human hippocampus
  • Irradiation induces neural precursor-cell dysfunction
  • Why avoid the hippocampus? A comprehensive review
  • Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001
  • CERR: a computational environment for radiotherapy research
  • Flattening filter free vs flattened beams for breast irradiation
  • Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies
  • Modeling freedom from progression for standard-risk medulloblastoma: a mathematical tumor control model with multiple modes of failure
  • Results of COG ACNS0331: a phase III trial of involved-field radiotherapy (IFRT) and low dose craniospinal irradiation (LD-CSI) with chemotherapy in average-risk medulloblastoma: a report from the children’s oncology group
  • Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy
  • Hippocampal sparing during craniospinal irradiation: what did we learn about the incidence of perihippocampus metastases?
  • Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy
  • Proton therapy - present and future
  • Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas
  • Compelling intelligent quotient change after treatment with proton versus photon radiation therapy for pediatric brain tumors
  • The role of image-guided intensity modulated proton therapy in glioma
  • Neurocognitive function and quality of life after proton beam therapy for brain tumor patients
  • Current therapy for medulloblastoma
  • Hippocampal radiotherapy dose-constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors
  • Real-time pretreatment review limits unacceptable deviations on a cooperative group radiation therapy technique trial: quality assurance results of RTOG 0933
  • IGRT has limited clinical value due to lack of accurate tumor delineation
  • Uncertainties in volume delineation in radiation oncology: a systematic review and recommendations for future studies
  • Towards achieving the full clinical potential of proton therapy by inclusion of LET and RBE models
  • Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios
  • Incidence of CNS injury for a cohort of 111 patients treated with proton therapy for medulloblastoma: LET and RBE associations for areas of injury